Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing

Michlene Passeri, Elizabeth Matthews, Ryan Kammeyer, Amanda L. Piquet

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Myelopathy is an increasingly recognized presentation of many antibody-mediated neuroinflammatory disorders. While specific features of certain autoimmune myelopathies such as aquaporin-4 antibody associated neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein associated disorder (MOGAD) are well-characterized, other less commonly seen antibody-associated myelopathies are not as well-defined. These include but are not limited to, Hu/ANNA1, anti-glial fibrillary acidic protein (GFAP), anti-CV2/collapsin response mediator protein (CRMP5), and amphiphysin. Here, we review the mentioned more common antibody mediated myelopathies as well those that as less common, followed by a review of differentials that may mimic these disorders.

Original languageEnglish (US)
Article number972143
JournalFrontiers in Neurology
Volume13
DOIs
StatePublished - Jul 28 2022
Externally publishedYes

Keywords

  • autoimmune manifestations
  • MOG antibody associated diseases
  • myelitis
  • myelopathy
  • NMO spectrum disorder (NMOSD)
  • paraneoplastic syndrome (PNS)

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing'. Together they form a unique fingerprint.

Cite this